Chemours

The Chemours Co. is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial. It operates through the following segments: Titanium Technologies, Thermal and Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment is involved in the manufacture of titanium dioxide pigment. The Thermal and Specialized Solutions segment offers refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment produces polymers and advanced materials that deliver attributes, including chemical inertness, thermal stability, low friction, weather and corrosion resistance, extreme temperature stability, and di-electric properties. The Chemical Solutions segment refers to the sale of chemicals used in industrial and consumer applications in the Americas. The company was founded on February 18, 2014, and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chemours overcomes Q4 challenges, eyes growth and sustainability in 2023

Chemours had a tough Q4 but a successful year overall, with a focus on margin improvement, growth in key businesses, and addressing legacy issues. The company is optimistic about 2023, emphasizing sustainability-led growth and returning value to shareholders.

Chemours reports strong Q1 performance, navigates challenges, eyes growth opportunities

Chemours' Q1 2023 Earnings Call highlighted strong performance, reaffirmed guidance, and emphasized margin improvement strategies. The company faces challenges from macroeconomic uncertainties and inflationary pressures but sees opportunities in sustainable initiatives and market-led innovation. Chemours remains confident in its full-year outlook and growth strategies.

Chemours reports record results, eyes cost reduction and innovation

Chemours had a strong quarter with record results and notable achievements in facility closures and settlements. While challenges lie ahead with a weaker second half expected, the company remains focused on shareholder value and strategic priorities. Opportunities in cost reduction, innovation, and market leadership position Chemours for future growth.

Chemours addresses challenges, eyes growth in sustainable solutions market

Chemours Company navigated challenges in Q3 2023, with a focus on long-term shareholder value and strategic transformation for performance improvement.
Strong performance in Performance Solutions and TSS business, alongside cost savings initiatives, position Chemours for future growth and margin recovery.
Management's commitment to driving value for shareholders amidst industry challenges underscores a proactive approach to addressing market dynamics.

Chemours reports Q4 sales growth, addresses TiO2 market challenges

Chemours is navigating challenges in the TiO2 market while focusing on cost reduction and growth opportunities in other segments. The company aims to maintain competitiveness through strategic decisions and investments in R&D. Analysts' inquiries during the earnings call highlighted concerns about leadership stability and various segment dynamics.

Chemours reports mixed Q1 results, eyes sequential growth in 2024

Chemours' Q1 2024 performance reflected mixed results across segments, with a focus on cost efficiencies, transformation plans, and maintaining liquidity amidst declining net sales and EBITDA.
Despite challenges in certain segments and market uncertainties, Chemours remains optimistic about sequential growth in the second quarter, aiming for significant EBITDA potential in 2024 and long-term financial improvement.
Strategic strengths in cost management, growth initiatives, and market opportunities position Chemours to navigate challenges, drive growth, and enhance profitability in a dynamic business environment.

Chemours exceeds volume expectations amidst challenges, anticipates sequential decline

Chemours demonstrated resilience and growth in key product lines despite facing challenges in Q1 and Q2.
The company's cost-saving efforts and recovery in certain segments highlight its ability to adapt to market conditions.
While financial results were impacted by one-time costs and a decline in net sales, Chemours maintained a strong net leverage ratio.
Anticipated sequential decline in net sales for Q3 underscores the need for strategic planning and operational optimization.

Chemours reports strong Q3 performance amidst strategic growth initiatives

Chemours' Q3 performance reflects operational strength and growth in key segments.
Challenges include declines in net sales for TSS and TT in Q4 and a net loss.
Opportunities exist in cost savings, growth in Opteon refrigerants, and strategic investments.
Overall, Chemours remains confident in its strategy to drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Chemours Co. is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial. It operates through the following segments: Titanium Technologies, Thermal and Specialized Solutions, Advanced Performance Materials, and Other. The Titanium Technologies segment is involved in the manufacture of titanium dioxide pigment. The Thermal and Specialized Solutions segment offers refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment produces polymers and advanced materials that deliver attributes, including chemical inertness, thermal stability, low friction, weather and corrosion resistance, extreme temperature stability, and di-electric properties. The Other segment consists of performance chemicals and intermediates business. The company was founded on February 18, 2014, and is headquartered in Wilmington, DE.

RADNOR, Pa. , May 6, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against The Chemours Company (NYSE: CC) ("Chemours" or the "Company") on behalf of investors who purchased or acquired Chemours common stock between February 10, 2023 and February 28, 2024, inclusive (the "Class Period").

The Chemours Company Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds The Chemours Company Shareholders of Deadline in Securities Fraud Class Action Lawsuit (CC)

NEW YORK , May 4, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of The Chemours Company (NYSE: CC) between February 10, 2023 and February 28, 2024, both dates inclusive (the "Class Period"), of the important May 20, 2024 lead plaintiff deadline. SO WHAT: If you purchased Chemours common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages The Chemours Company Investors to Secure Counsel Before Important Deadline in Securities Class Action - CC

NEW ORLEANS , May 3, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 20, 2024 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company (NYSE: CC), if they purchased or otherwise acquired the Company's shares between February 10, 2023, and February 28, 2024, inclusive (the "Class Period").  This action is pending in the United States District Court for the District of Delaware.

THE CHEMOURS COMPANY SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against The Chemours Company - CC

NEW YORK, NY / ACCESSWIRE / May 3, 2024 / If you suffered a loss on your The Chemours Company (NYSE:CC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/the-chemours-company-lawsuit-submission-form?prid=78084&wire=1 or contact Joseph E. Levi, Esq.

The Chemours Company Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – CC

NEW YORK , May 3, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Chemours Company ("Chemours" or the "Company") (NYSE: CC) and reminds investors of the May 20, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Chemours To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Chemours stock or options between February 10, 2023 and February 28, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Chemours

WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours Discontinues U.S. Sales of Legacy Freon™ Refrigerants 404A and 507.

Chemours Discontinues U.S. Sales of Legacy Freon™ Refrigerants 404A and 507

RADNOR, Pa. , May 1, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against The Chemours Company (NYSE: CC) ("Chemours" or the "Company") on behalf of investors who purchased or acquired Chemours common stock between February 10, 2023 and February 28, 2024, inclusive (the "Class Period").

Lead Plaintiff Deadline on May 20, 2024 for The Chemours Company Investors - Kessler Topaz Meltzer & Check, LLP Reminds Investors of Class Action Lawsuit Filed Against The Chemours Company

Chemours Co (NYSE:CC ) Q1 2024 Results Conference Call May 1, 2024 8:00 AM ET Company Participants Brandon Ontjes - Vice President of Investor Relations Denise Dignam - President and Chief Executive Officer Matt Abbott - Chief Financial Officer Conference Call Participants Duffy Fischer - Goldman Sachs John McNulty - BMO Capital Markets Josh Spector - UBS Financial Hassan Ahmed - Alembic Global Advisors Mike Leithead - Barclays Turner Hinrichs - Morgan Stanley Operator Good morning. My name is Lovely, and I will be your conference operator today.

Chemours Co (CC) Q1 2024 Earnings Call Transcript

Lower volumes and prices hurt Chemours' (CC) top line in the first quarter.

Chemours (CC) Earnings Beat, Revenues Miss Estimates in Q1

The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Chemours (CC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Chemours (CC) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.98 per share a year ago.

Chemours (CC) Q1 Earnings Surpass Estimates

NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your The Chemours Company (NYSE:CC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/the-chemours-company-lawsuit-submission-form?prid=77637&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on The Chemours Company(CC)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--The Chemours Company Reports First Quarter 2024 Results.

The Chemours Company Reports First Quarter 2024 Results

NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your The Chemours Company (NYSE:CC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/the-chemours-company-lawsuit-submission-form?prid=77599&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of The Chemours Company (CC) Shareholders

WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours Announces Second Quarter Dividend.

Chemours Announces Second Quarter Dividend

LOS ANGELES, CA / ACCESSWIRE / April 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company ("Chemours" or "the Company") (NYSE:CC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 10, 2023 and February 28, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2024.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in The Chemours Company with Losses of $100,000 to Contact the Firm

RADNOR, Pa. , April 27, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against The Chemours Company (NYSE: CC) ("Chemours" or the "Company") on behalf of investors who purchased or acquired Chemours common stock between February 10, 2023 and February 28, 2024, inclusive (the "Class Period").

The Chemours Company Investors: May 20, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

NEW ORLEANS , April 26, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 20, 2024 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company (NYSE: CC), if they purchased or otherwise acquired the Company's shares between February 10, 2023, and February 28, 2024, inclusive (the "Class Period").

THE CHEMOURS COMPANY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against The Chemours Company - CC

Chemours (CC) reported earnings 30 days ago. What's next for the stock?

Chemours (CC) Up 2.9% Since Last Earnings Report: Can It Continue?

NEW YORK , April 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of The Chemours Company (NYSE: CC). Shareholders who purchased shares of CC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

May 20, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against CC

NEW YORK , April 25, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of The Chemours Company (NYSE: CC) between February 10, 2023 and February 28, 2024, both dates inclusive (the "Class Period"), of the important May 20, 2024 lead plaintiff deadline. SO WHAT: If you purchased Chemours common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages The Chemours Company Investors to Secure Counsel Before Important Deadline in Securities Class Action - CC

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your The Chemours Company (NYSE:CC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/the-chemours-company-lawsuit-submission-form?prid=77063&wire=1 or contact Joseph E. Levi, Esq.

The Chemours Company Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 20, 2024 to Discuss Your Rights – CC

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your The Chemours Company (NYSE:CC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/the-chemours-company-lawsuit-submission-form?prid=77024&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on The Chemours Company (CC) should contact Levi & Korsinsky about pending Class Action - CC

WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours Announces Dates for First Quarter 2024 Earnings Release and Webcast Conference Call.

Chemours Announces Dates for First Quarter 2024 Earnings Release and Webcast Conference Call

LOS ANGELES , April 23, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Chemours Company ("Chemours" or "the Company") (NYSE: CC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against The Chemours Company and Encourages Investors with Losses to Contact the Firm

News for Chemours Stock (CC)